9888À­Ë¹Î¬¼Ó˹

9888À­Ë¹Î¬¼Ó˹(¹É·Ý)ÓÐÏÞ¹«Ë¾-¹Ù·½ÍøÕ¾
ÎÒÃǵķþÎñ

×÷ΪÖйúµÚÈý·½¼ì²âÓëÈÏÖ¤·þÎñµÄ¿ªÍØÕߺÍÁìÏÈÕß £¬CTI9888À­Ë¹Î¬¼Ó˹¼ì²âΪȫÇò¿Í»§ÌṩһվʽĥÁ·¡¢²âÊÔ¡¢Ð£×¼¡¢ÈÏÖ¤¼°ÊÖÒÕ·þÎñ¡£

9888À­Ë¹Î¬¼Ó˹(¹É·Ý)ÓÐÏÞ¹«Ë¾-¹Ù·½ÍøÕ¾
ÐÐÒµ½â¾ö¼Æ»®

·þÎñÄÜÁ¦ÒÑÖÜÈ«ÁýÕÖµ½·ÄÖ¯´ò°ç¼°Ð¬°ü¡¢Ó¤Í¯Íæ¾ß¼°¼Ò¾ÓÉúÑÄ¡¢µç×ÓµçÆ÷¡¢Ò½Ñ§¿µ½¡¡¢Ê³Îï¼°Å©²úÆ·……µÈÐÐÒµµÄ¹©Ó¦Á´ÉÏÏÂÓΡ£

9888À­Ë¹Î¬¼Ó˹(¹É·Ý)ÓÐÏÞ¹«Ë¾-¹Ù·½ÍøÕ¾
ÌØÉ«·þÎñ

ÖÜÈ«°ü¹ÜÆ·ÖÊÓëÇå¾² £¬Íƶ¯ºÏ¹æÓëÁ¢Òì £¬ÕÃÏÔÆ·ÅƾºÕùÁ¦ £¬ÊµÏÖ¸ü¸ßÖÊÁ¿¡¢¸ü¿µ½¡¡¢¸üÇå¾²¡¢¸üÂÌÉ«µÄ¿ÉÒ»Á¬Éú³¤¡£

¼ÓÈëÎÒÃÇ
È˲ÅÕþ²ß
ÕÐÏÍÄÉÊ¿
9888À­Ë¹Î¬¼Ó˹(¹É·Ý)ÓÐÏÞ¹«Ë¾-¹Ù·½ÍøÕ¾
È˲ÅÕþ²ß
°ü¹ÜÔ±¹¤»ù±¾È¨ÒæÓ븣Àû£»ÌṩרҵÊÖÒÕÅàѵ £¬Ôö½øÔ±¹¤Éú³¤£»¿ªÕ¹¸»ºñ¶à²ÊµÄ»î¶¯ £¬Æ½ºâÔ±¹¤ÊÂÇéÓëÉúÑÄ¡£
9888À­Ë¹Î¬¼Ó˹(¹É·Ý)ÓÐÏÞ¹«Ë¾-¹Ù·½ÍøÕ¾
ÕÐÏÍÄÉÊ¿
½Ó´ý¼ÓÈë9888À­Ë¹Î¬¼Ó˹¼ì²â¸÷ÈËÍ¥ £¬ÎÒÃǽ«ÎªÄã´î½¨Ò»¸ö³ä·ÖÑéÕ¹²Å»ª £¬ÊµÏÖÖ°ÒµÀíÏëµÄÎę̀¡£
9888À­Ë¹Î¬¼Ó˹(¹É·Ý)ÓÐÏÞ¹«Ë¾-¹Ù·½ÍøÕ¾
ÐÂÎÅ×ÊѶ

·Î°©ÔçɸÉúÎï±ê¼ÇÎïµÄÑо¿Ï£Íû

Ðû²¼Ê±¼ä£º2024-08-21 ä¯ÀÀ´ÎÊý£º1217

·Î°©ÊÇ·¢²¡ÂÊ×î¸ßµÄÖ×Áö £¬Ñо¿Åú×¢ £¬·Î°©µÄÔçÆÚɸ²éºÍÕï¶ÏÄܹ»¼«´óµÄÌá¸ßÎåÄêÉúÑÄÂÊ¡£Cancers(Basel)½ÒÏþһƪÌâΪNon-Invasive Biomarkers for Early Lung Cancer DetectionµÄ×ÛÊö £¬ÖÜÈ«ÏÈÈÝÁ˷ΰ©ÔçɸÉúÎï±ê¼ÇÎïµÄÑо¿Ï£Íû¡£

 

9888À­Ë¹Î¬¼Ó˹(¹É·Ý)ÓÐÏÞ¹«Ë¾-¹Ù·½ÍøÕ¾


 ±¾Æª×ÛÊöÊ×ÏÈÌá³ö £¬ÀíÏëµÄÖ×ÁöÉúÎï±ê¼ÇÎïÓ¦¸Ã¾ßÓÐÒÔÏÂÌØÕ÷£º

(1) Çå¾²¡¢Ò×ÓÚÊÕÂ޺ͼì²â £¬¾ßÓб¾Ç®Ð§Ò棻

(2) ²»ÊÜÐÔ±ð»òÖÖ×åµÈÖ÷ÒªÉú³Ýͳ¼ÆÊý¾ÝµÄÓ°Ï죻

(3) ¸ßѸËÙ¶È¿É׼ȷ·¢Ã÷ÔçÆÚ°©Ö¢£»

(4) ×îÉÙµÄÈËÁ¦Í¶Èë £¬ÌØÊâÊÇ´ó×ÚÊý¾ÝµÄÆÊÎö £¬ÒÔïÔÌ­¶ÔÈËÁ¦×ÊÔ´µÄÓ°Ïì¡£

 

Ðí¶à·ÇÇÖÈëÐÔÉúÎï±ê¼ÇÎï £¬ÈçctDNA¡¢CTC¡¢ÂѰ×ÖÊ¡¢Ö¬ÖÊ¡¢RNAºÍmicroRNA£¨miRNA£© £¬¿ÉÒÔÔÚѪ½¬¡¢ÑªÇå¡¢ÄòÒº¡¢ÍÙÒº¡¢¸¹Ë®ºÍÄÔ¼¹ÒºµÈÌåÒºÖмì²âµ½¡£ÕâЩÉúÎï±ê¼ÇÎï±»ÆÕ±éÑо¿ £¬È»¶ø £¬ÓÉÓÚ»ùÒò×éµÄ²»ÎȹÌÐÔ £¬ÒÔ¼°·Î°©Ï¸°ûµÄÒ»Á¬Ñݱä £¬ÉúÎï±ê¼ÇÎïµÄ±í´ï»áÓкܴóµÄת±ä £¬ÀíÏëµÄÉúÎï±ê¼ÇÎïÉÐδ·¢Ã÷¡£

 

DNA¼×»ù»¯

·Î°©±í¹ÛÒÅ´«×ª±äÊdz£¼ûµÄ £¬Ñª½¬ÖÐDNA¼×»ù»¯µÄ¼ì²â £¬×÷Ϊɸ²éºÍÕï¶Ï·Î°©µÄ°×±ê¼ÇÎï £¬Ò²ÏÔʾ³öÔ¶¾°¡£BearzattoµÈÈ˱¨µÀÁËp16INK4A¼×»ù»¯ÔÚÔçÆÚÏÙ°©Ñª½¬Ñù±¾ÖÐÆµÂÊÔöÌí¡£Í¬Ñù £¬ÑªÒºÑù±¾Öмì²âµ½µÄRASSF1AºÍCDKN2A¼×»ù»¯ÔÚÔçÆÚ·Î°©Öо­³£±»·¢Ã÷ £¬¾Ý±¨µÀÃô¸ÐÐÔΪ22%ÖÁ66% £¬ÌØÒìÐÔΪ57-100%¡£

 

microRNA(miRNA)

miRNAÊdz¤¶ÈΪ18-25¸öºËÜÕËáµÄСÐͷDZàÂëRNA £¬¼ÓÈë»ùÒò±í´ïת¼ºóµ÷¿Ø¡£ËüÃÇÔÚ°üÀ¨°©Ö¢ÔÚÄÚµÄÐí¶à²¡ÀíÌõ¼þÏÂÒì³£±í´ï £¬²¢ÇÒ¿ÉÒÔÔÚÄòÒº¡¢ÌµÒººÍѪҺÖмì²âµ½ £¬Ê¹ËüÃdzÉΪ°©Ö¢¼ì²âµÄÉúÎï±ê¼ÇÎï¡£miRNA¿ÉÒÔ×÷ΪÖ×ÁöÒÖÖÆÒò×Ó»ò°©»ùÒò £¬ÉõÖÁÁ½Õß¼æ¶øÓÐÖ®¡£±ðµÄ £¬miRNAÔÚ°©Ö¢±¬·¢Éú³¤µÄÕû¸öÀú³ÌÖмá³ÖÎȹÌÐÔ £¬ÓÉÓÚËüÃÇ̫С¶øÎÞ·¨½µ½â £¬²¢ÇÒһЩmiRNAÔÚÍâÃÚÌåÖнøÒ»²½Êܵ½±£»¤¡£Òò´Ë £¬miRNA±»ÒÔΪÊǰ©Ö¢Õï¶ÏºÍ¼à²âµÄÒ»¸öÓÐÎüÒýÁ¦µÄÉúÎï±ê¼ÇÎï¡£

 

ÔÚYanaiharaµÈÈ˵ÄÔçÆÚÑо¿ÖÐ £¬miR-17-3p¡¢miR-21¡¢miR-106a¡¢miR-146¡¢miR-155¡¢miR-191¡¢miR-192¡¢miR-203¡¢miR-205¡¢miR-210¡¢miR-212ºÍmiR-214µÈ12ÖÖmicroRNAÔÚ²î±ðµÄ¶ñÐÔ×éÖ¯Öбí´ï²î±ð £¬±»ÅжÏÎªÇø·Ö·Î°©ºÍÁ¼ÐÔ·Î×éÖ¯µÄDZÔÚÉúÎï±ê¼ÇÎï¡£WozniakµÈÈ˵ÄÁíÒ»ÏîÑо¿Åú×¢ £¬24ÖÖmiRNAµÄ×éºÏÄܹ»½«·Î°©²¡ÀýÓ뿵½¡±ÈÕÕÇøÍÑÀëÀ´¡£×÷ÕßÒÔΪ £¬ÉÏÊömiRNAÔÚѪ½¬ÖеĹý±í´ï¿É×÷ΪÔçÆÚ¼ì²âNSCLCµÄÉúÎï±ê¼ÇÎï £¬ÖµµÃ½øÒ»²½Ñо¿¡£

 

ctDNA

ctDNA£¨Ñ­»·Ö×ÁöDNA£©°üÀ¨ÑªÒº»òÆäËûÌåÒºÖб»°ü¹üµÄ£¨ÔÚÑ­»·ÄÒÅÝÖУ©ºÍδ±»°ü¹üµÄÓÎÀëDNA £¬ctDNAÊÇÒ»ÖÖºÜÓÐǰ;µÄÉúÎï±ê¼ÇÎï¡£

 

9888À­Ë¹Î¬¼Ó˹(¹É·Ý)ÓÐÏÞ¹«Ë¾-¹Ù·½ÍøÕ¾
ͼ1  ctDNAºÍ×éÖ¯»î¼ìµÄÖ÷񻂿±ð

 

×îºó £¬±¾Æª×ÛÊöÖ¸³ÊÏÖÔÚ¿ª·¢ÓÐÓúͿɿ¿µÄÖ×ÁöÉúÎï±ê¼ÇÎï±£´æµÄÌôÕ½£º

(1) ȱ·¦“ÀíÏëµÄ”ÉúÎï±ê¼ÇÎï×÷Ϊ½ð±ê×¼ £¬Ê¹µÃÑé֤еÄÉúÎï±ê¼ÇÎïÒÔÓÐÓÃÕï¶Ï°©Ö¢ £¬¼´½¨ÉèÁÙ´²Ïà¹ØÐÔºÍÊÊÓÃÐÔ¾ßÓÐÌôÕ½ÐÔ¡£

(2) Ö×Áö½ø»¯²»¿É×èÖ¹µØµ¼ÖÂÍ»±ä¶àÑùÐÔ £¬µ¼ÖÂÖ×Áö¼äºÍÖ×ÁöÄÚµÄÒìÖÊÐÔ £¬´Ó¶øµ¼ÖÂÌØ¶¨Ô­·¢Ö×ÁöÖÐÉúÎï±ê¼ÇÎïµÄת±ä¡£

(3) ÉúÎï±ê¼ÇÎïµÄÖØ´óÐԺͶ¯Ì¬×ª±ä£¨ÌØÊâÊÇÔÚѪ½¬ÖУ©Ê¹µÃÔÚͳһ»¼ÕßÖлòÔÚ»¼ÕßÖ®¼ä¾ÙÐнÏÁ¿Ê±ºÜÊÇÄÑÌâ¡£

(4) Ðí¶àÌØÒìÐÔÉúÎï±ê¼ÇÎïµÄÏà¶ÔƷò½ÏµÍ £¬Í¨³£»áµ¼Ö¼ÙÒõÐÔЧ¹û £¬Òò´ËÌØÒìÐԽϵÍ¡£

(5) ÑùÆ·ÍøÂç¡¢Öü´æ¡¢ÔËÊäºÍÊÖÒÕÖеıäÁ¿ £¬¿ÉÄܵ¼ÖÂЧ¹û·×ÆçÖ £¬¶ÔÉúÎï±ê¼ÇÎïµÄÓÐÓÃÐԺͿɿ¿ÐÔ±¬·¢µ¹ÔËÓ°Ïì¡£

(6) ÓëÐÂÒ©¿ª·¢ÃæÁÙµÄÌôÕ½ÀàËÆ £¬°©Ö¢ÐÂÉúÎï±ê¼ÇÎïµÄ¿ª·¢Éæ¼°´ÓʵÑéÊÒ¹âÁÙ´²µÄÖØ´ó¡¢Âþ³¤ÇÒÌÚ¹óµÄ·¾¶¡£

 

²Î¿¼ÎÄÏ×

Cancers (Basel). 2022 Nov 24; 14(23): 5782. doi: 10.3390/cancers14235782.

ÍøÕ¾µØÍ¼